- Home
- GCTS vs HLVX Comparison
GCTS vs HLVX Comparison
Compare GCTS & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- HLVX
- Stock Information
- Founded
- GCTS 1998
- HLVX 2020
- Country
- GCTS United States
- HLVX United States
- Employees
- GCTS N/A
- HLVX N/A
- Industry
- GCTS Blank Checks
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- GCTS Finance
- HLVX Health Care
- Exchange
- GCTS Nasdaq
- HLVX Nasdaq
- Market Cap
- GCTS 91.7M
- HLVX 83.7M
- IPO Year
- GCTS N/A
- HLVX 2022
- Fundamental
- Price
- GCTS $1.45
- HLVX $1.69
- Analyst Decision
- GCTS Strong Buy
- HLVX Hold
- Analyst Count
- GCTS 1
- HLVX 5
- Target Price
- GCTS $5.00
- HLVX $2.33
- AVG Volume (30 Days)
- GCTS 220.2K
- HLVX 273.4K
- Earning Date
- GCTS 05-13-2025
- HLVX 05-08-2025
- Dividend Yield
- GCTS N/A
- HLVX N/A
- EPS Growth
- GCTS N/A
- HLVX N/A
- EPS
- GCTS N/A
- HLVX N/A
- Revenue
- GCTS $9,128,000.00
- HLVX N/A
- Revenue This Year
- GCTS $315.69
- HLVX N/A
- Revenue Next Year
- GCTS $170.56
- HLVX N/A
- P/E Ratio
- GCTS N/A
- HLVX N/A
- Revenue Growth
- GCTS N/A
- HLVX N/A
- 52 Week Low
- GCTS $1.16
- HLVX $1.34
- 52 Week High
- GCTS $7.00
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- GCTS 41.08
- HLVX 55.97
- Support Level
- GCTS $1.37
- HLVX $1.62
- Resistance Level
- GCTS $1.57
- HLVX $1.75
- Average True Range (ATR)
- GCTS 0.16
- HLVX 0.12
- MACD
- GCTS 0.01
- HLVX 0.03
- Stochastic Oscillator
- GCTS 41.84
- HLVX 85.37
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.